Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12605000138684
Ethics application status
Approved
Date submitted
9/08/2005
Date registered
12/08/2005
Date last updated
18/12/2017
Type of registration
Retrospectively registered
Titles & IDs
Public title
Advanced GIST
Query!
Scientific title
Phase III, randomised, intergroup, international trial assessing the clinical activity of STI571 at two dose levels in patients with unresectable or metastatic gastrointestional stromal tumors (GIST) expressing the kit receptor tyrosine kinase (CD117)
Query!
Secondary ID [1]
114
0
European Organisation for Research and Treatment of Cancer (EORTC): EORTC 62005
Query!
Secondary ID [2]
115
0
National Clinical Trials Registry: NCTR465
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Advanced GIST
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Patients with unresectable or metastatic gastrointestional stromal tumors (GIST) expressing the kit receptor tyrosine kinase (CD117)
228
0
Query!
Condition category
Condition code
Cancer
259
259
0
0
Query!
Stomach
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
It is the study of two doses (400mg and 800mg) of STI571 (Imatinib mesylate) to test whether any relevant dose/activity relationship is detectable in patients with unresectable or metastatic gastrointestional stromal tumors (GIST) expressing the kit receptor tyrosine kinase (CD117). Patients will receive study drug until disease progression or unacceptable toxicity.
Query!
Intervention code [1]
138
0
Treatment: Drugs
Query!
Comparator / control treatment
No comparator
Query!
Control group
Dose comparison
Query!
Outcomes
Primary outcome [1]
304
0
To compare the outcome of patients with with unresectable or metastatic gastrointestional stromal tumors (GIST) expressing the kit receptor tyrosine kinase (CD117) treated with low versus high doses of STI571.
Query!
Assessment method [1]
304
0
Query!
Timepoint [1]
304
0
After 170 events (progression or death)
Query!
Secondary outcome [1]
675
0
To assess response rates of patients with these two doses of STI571.
Query!
Assessment method [1]
675
0
Query!
Timepoint [1]
675
0
After 170 events (progression or death)
Query!
Secondary outcome [2]
676
0
To assess toxicities of patients with these two doses of STI571.
Query!
Assessment method [2]
676
0
Query!
Timepoint [2]
676
0
After 170 events (progression or death)
Query!
Eligibility
Key inclusion criteria
1. Documented diagnosis of GIST with kit expression. 2. At lease one measureable or evaluable site of disease. 3. Performance status 0,1,2 or 3 (ECOG).
Query!
Minimum age
Not stated
Query!
Query!
Maximum age
Not stated
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1.Patient has received chemotherapy or any other investigational agent within in last 28 days 2. Patient with Grade III/IV cardiac problems 3. Known brain metastasis
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation was made from a central website - EORTC.
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Random allocation sequence stratification by institution, measurability of disease (measurable versus non-measurable) and performance status (WHO 0-2 Vs 3)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Crossover
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Safety/efficacy
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Date of first participant enrolment
Anticipated
7/02/2001
Query!
Actual
13/06/2001
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
7/02/2002
Query!
Date of last data collection
Anticipated
Query!
Actual
10/10/2016
Query!
Sample size
Target
946
Query!
Accrual to date
Query!
Final
946
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,TAS,WA,VIC
Query!
Recruitment hospital [1]
9583
0
Royal Prince Alfred Hospital - Camperdown
Query!
Recruitment hospital [2]
9584
0
Royal North Shore Hospital - St Leonards
Query!
Recruitment hospital [3]
9585
0
Westmead Hospital - Westmead
Query!
Recruitment hospital [4]
9586
0
Prince of Wales Hospital - Randwick
Query!
Recruitment hospital [5]
9587
0
St George Hospital - Kogarah
Query!
Recruitment hospital [6]
9588
0
Bankstown-Lidcombe Hospital - Bankstown
Query!
Recruitment hospital [7]
9589
0
Flinders Medical Centre - Bedford Park
Query!
Recruitment hospital [8]
9590
0
Ashford Cancer Centre: Adelaide Cancer Centre - Kurralta Park
Query!
Recruitment hospital [9]
9591
0
Peter MacCallum Cancer Centre - Melbourne
Query!
Recruitment hospital [10]
9592
0
Barwon Health - Geelong Hospital campus - Geelong
Query!
Recruitment hospital [11]
9593
0
Western Hospital - Footscray
Query!
Recruitment hospital [12]
9594
0
Royal Brisbane & Womens Hospital - Herston
Query!
Recruitment hospital [13]
9595
0
Princess Alexandra Hospital - Woolloongabba
Query!
Recruitment hospital [14]
9596
0
The Wesley Hospital - Auchenflower
Query!
Recruitment hospital [15]
9597
0
Launceston General Hospital - Launceston
Query!
Recruitment hospital [16]
9598
0
Sir Charles Gairdner Hospital - Nedlands
Query!
Recruitment hospital [17]
9599
0
Royal Perth Hospital - Perth
Query!
Recruitment postcode(s) [1]
18342
0
2031 - Randwick
Query!
Recruitment postcode(s) [2]
18339
0
2050 - Camperdown
Query!
Recruitment postcode(s) [3]
18340
0
2065 - St Leonards
Query!
Recruitment postcode(s) [4]
18341
0
2145 - Westmead
Query!
Recruitment postcode(s) [5]
18344
0
2200 - Bankstown
Query!
Recruitment postcode(s) [6]
18343
0
2217 - Kogarah
Query!
Recruitment postcode(s) [7]
18347
0
3000 - Melbourne
Query!
Recruitment postcode(s) [8]
18348
0
3220 - Geelong
Query!
Recruitment postcode(s) [9]
18350
0
4029 - Herston
Query!
Recruitment postcode(s) [10]
18352
0
4066 - Auchenflower
Query!
Recruitment postcode(s) [11]
18351
0
4102 - Woolloongabba
Query!
Recruitment postcode(s) [12]
18349
0
5022 - Henley Beach
Query!
Recruitment postcode(s) [13]
18346
0
5037 - Kurralta Park
Query!
Recruitment postcode(s) [14]
18345
0
5042 - Bedford Park
Query!
Recruitment postcode(s) [15]
18355
0
6000 - Perth
Query!
Recruitment postcode(s) [16]
18354
0
6009 - Nedlands
Query!
Recruitment postcode(s) [17]
18353
0
7250 - Launceston
Query!
Recruitment outside Australia
Country [1]
9442
0
New Zealand
Query!
State/province [1]
9442
0
Wellington
Query!
Country [2]
9443
0
Singapore
Query!
State/province [2]
9443
0
Singapore
Query!
Funding & Sponsors
Funding source category [1]
313
0
Commercial sector/Industry
Query!
Name [1]
313
0
Novartis Australia
Query!
Address [1]
313
0
54 Waterloo Road North Ryde NSW 2113
Query!
Country [1]
313
0
Australia
Query!
Funding source category [2]
314
0
Charities/Societies/Foundations
Query!
Name [2]
314
0
EORTC
Query!
Address [2]
314
0
AISBL / IVZW Avenue Mounierlaan, 83/11. Brussel 1200 Bruxelles, Belgie Belgique
Query!
Country [2]
314
0
Belgium
Query!
Primary sponsor type
Commercial sector/Industry
Query!
Name
Novartis Australia
Query!
Address
54 Waterloo Road North Ryde NSW 2113
Query!
Country
Australia
Query!
Secondary sponsor category [1]
244
0
Charities/Societies/Foundations
Query!
Name [1]
244
0
EORTC
Query!
Address [1]
244
0
AISBL / IVZW Avenue Mounierlaan, 83/11. Brussel 1200 Bruxelles, Belgie Belgique
Query!
Country [1]
244
0
Belgium
Query!
Other collaborator category [1]
279871
0
Other Collaborative groups
Query!
Name [1]
279871
0
Australasian Gastro-Intestinal Trials Group
Query!
Address [1]
279871
0
Level 6
The Chris O'Brien Lifehouse
119-146 Missenden Rd
Camperdown 2050
Query!
Country [1]
279871
0
Australia
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
1186
0
University of Sydney HREC
Query!
Ethics committee address [1]
1186
0
Query!
Ethics committee country [1]
1186
0
Australia
Query!
Date submitted for ethics approval [1]
1186
0
Query!
Approval date [1]
1186
0
11/05/2001
Query!
Ethics approval number [1]
1186
0
Query!
Ethics committee name [2]
1187
0
Royal North Shore
Query!
Ethics committee address [2]
1187
0
Query!
Ethics committee country [2]
1187
0
Australia
Query!
Date submitted for ethics approval [2]
1187
0
Query!
Approval date [2]
1187
0
Query!
Ethics approval number [2]
1187
0
Query!
Ethics committee name [3]
1188
0
Westmead
Query!
Ethics committee address [3]
1188
0
Query!
Ethics committee country [3]
1188
0
Australia
Query!
Date submitted for ethics approval [3]
1188
0
Query!
Approval date [3]
1188
0
Query!
Ethics approval number [3]
1188
0
Query!
Ethics committee name [4]
1189
0
Prince of Wales
Query!
Ethics committee address [4]
1189
0
Query!
Ethics committee country [4]
1189
0
Australia
Query!
Date submitted for ethics approval [4]
1189
0
Query!
Approval date [4]
1189
0
Query!
Ethics approval number [4]
1189
0
Query!
Ethics committee name [5]
1190
0
St George
Query!
Ethics committee address [5]
1190
0
Query!
Ethics committee country [5]
1190
0
Australia
Query!
Date submitted for ethics approval [5]
1190
0
Query!
Approval date [5]
1190
0
Query!
Ethics approval number [5]
1190
0
Query!
Ethics committee name [6]
1191
0
Bankstown-Lidcombe
Query!
Ethics committee address [6]
1191
0
Query!
Ethics committee country [6]
1191
0
Australia
Query!
Date submitted for ethics approval [6]
1191
0
Query!
Approval date [6]
1191
0
Query!
Ethics approval number [6]
1191
0
Query!
Ethics committee name [7]
1192
0
Peter MacCallum
Query!
Ethics committee address [7]
1192
0
Query!
Ethics committee country [7]
1192
0
Australia
Query!
Date submitted for ethics approval [7]
1192
0
Query!
Approval date [7]
1192
0
Query!
Ethics approval number [7]
1192
0
Query!
Ethics committee name [8]
1193
0
Geelong
Query!
Ethics committee address [8]
1193
0
Query!
Ethics committee country [8]
1193
0
Australia
Query!
Date submitted for ethics approval [8]
1193
0
Query!
Approval date [8]
1193
0
Query!
Ethics approval number [8]
1193
0
Query!
Ethics committee name [9]
1194
0
Western General
Query!
Ethics committee address [9]
1194
0
Query!
Ethics committee country [9]
1194
0
Australia
Query!
Date submitted for ethics approval [9]
1194
0
Query!
Approval date [9]
1194
0
Query!
Ethics approval number [9]
1194
0
Query!
Ethics committee name [10]
1195
0
Royal Brisbane
Query!
Ethics committee address [10]
1195
0
Query!
Ethics committee country [10]
1195
0
Australia
Query!
Date submitted for ethics approval [10]
1195
0
Query!
Approval date [10]
1195
0
Query!
Ethics approval number [10]
1195
0
Query!
Ethics committee name [11]
1196
0
Princess Alexandra
Query!
Ethics committee address [11]
1196
0
Query!
Ethics committee country [11]
1196
0
Australia
Query!
Date submitted for ethics approval [11]
1196
0
Query!
Approval date [11]
1196
0
Query!
Ethics approval number [11]
1196
0
Query!
Ethics committee name [12]
1197
0
Wesley Medical Centre
Query!
Ethics committee address [12]
1197
0
Query!
Ethics committee country [12]
1197
0
Australia
Query!
Date submitted for ethics approval [12]
1197
0
Query!
Approval date [12]
1197
0
Query!
Ethics approval number [12]
1197
0
Query!
Ethics committee name [13]
1198
0
Ashford Medical Centre
Query!
Ethics committee address [13]
1198
0
Query!
Ethics committee country [13]
1198
0
Australia
Query!
Date submitted for ethics approval [13]
1198
0
Query!
Approval date [13]
1198
0
Query!
Ethics approval number [13]
1198
0
Query!
Ethics committee name [14]
1199
0
Sir Charles Gairdner
Query!
Ethics committee address [14]
1199
0
Query!
Ethics committee country [14]
1199
0
Australia
Query!
Date submitted for ethics approval [14]
1199
0
Query!
Approval date [14]
1199
0
Query!
Ethics approval number [14]
1199
0
Query!
Ethics committee name [15]
1200
0
Royal Perth
Query!
Ethics committee address [15]
1200
0
Query!
Ethics committee country [15]
1200
0
Australia
Query!
Date submitted for ethics approval [15]
1200
0
Query!
Approval date [15]
1200
0
Query!
Ethics approval number [15]
1200
0
Query!
Ethics committee name [16]
1201
0
Launceston General
Query!
Ethics committee address [16]
1201
0
Query!
Ethics committee country [16]
1201
0
Australia
Query!
Date submitted for ethics approval [16]
1201
0
Query!
Approval date [16]
1201
0
Query!
Ethics approval number [16]
1201
0
Query!
Ethics committee name [17]
299252
0
Royal Prince Alfred Hospital HREC
Query!
Ethics committee address [17]
299252
0
Missenden Rd Camperdown NSW
Query!
Ethics committee country [17]
299252
0
Australia
Query!
Date submitted for ethics approval [17]
299252
0
Query!
Approval date [17]
299252
0
31/05/2001
Query!
Ethics approval number [17]
299252
0
Query!
Summary
Brief summary
This is a randomised, open label, multicentre clinical trial of two different doses of imatinib to test whether there is any difference in disease outcome between the doses in patients with unresectable or metastatic malignant gastrointestinal stromal tumours (GIST). Recruitment opened in 2001, closed in 2002 with 946 patients worldwide and 116 at Australian, NZ and Singapore sites. Long term Follow UP closed October 2016.
Query!
Trial website
Query!
Trial related presentations / publications
1. Verweij J, Casali P, Zalcberg J, Le Cesne A, Reichardt P, Blay J-Y, Issels R, van Oosterom A, Hogendoorn P, van Glabbeke M, Judson I, Bertulli R, Judson I, for the EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group and the Australian Gastro-intestinal trials group: Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004; 364: 1127–1134. 2. Zalcberg J, Verweij J, Casali P, Le Cesne A, Reichardt P, Blay J, Schlemmer M, Van Glabbeke M, Brown M, Judson I, EORTC Soft Tissue and Bone Sarcoma Group tISGAG-ITG. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. European Journal of Cancer 2005; 41(12): 1751-1757. 3. Van Glabbeke M, Verweij J, Casali P, Le Cesne A, Hohenberger P, Ray-Coquard I, Schlemmer M, van Oosterom A, Goldstein D, Sciot R, Hogendoorn P, Brown M, Bertulli R, Judson I. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group–Australasian Gastro-Intestinal Trials Group Study. Journal of Clinical Oncology 2005; 23(24): 5795-5804. 4. Goldstein D, Tan B, Rossleigh M, Haindl W, Walker B, Dixon J. Gastrointestinal stromal tumours: correlation of F-18-FDG gamma camera-based coincidence positron emission tomography with CT for the assessment of treatment respons--an AGITG study. Oncology 2005; 69(4): 326-332. 5. Van Glabbeke M, Verweij J, Casali PG, Simes J, Cesne AL, Reichardt P, Issels R, Judson IR, van Oosterom AT, Blay JY. Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC- IS G-AGITG). European Journal of Cancer 2006; 42(14): 2277–2285. 6. Tamborini E, Bonadiman L, Greco A, Albertini V, Negri T, Gronchi A, Bertulli R, Colecchia M, Casali P, Pierotti M, Pilotti S. A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology 2004; 127(1): 294–299. 7. Debiec-Rychter M, Sciot R, Le Cesne A, Schlemmer M, Hohenberger P, van Oosterom AT, Blay JY, Leyvraz S, Stul M, Casali PG, Zalcberg J, Verweij J, Van Glabbeke M, Hagemeijer A, Judson I; On behalf of the EORTC Soft Tissue and Bone Sarcoma Group, The Italian Sarcoma Group and the Australasian Gastro-Intestinal Trials Group. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. European Journal of Cancer 2006; 42(8): 1093–103. 8. Verweij J, Casali PG, Kotasek D, LeCesne A, Reichard P, Judson IR, Issels R, Van Oosterom AT, Van Glabbeke M, Blay J-Y. Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005. European Journal of Cancer 2007; 43: 974–978. 9. Romeo S, Debiec-Rychter M, Van Glabbeke M, Van Paassen H, Comite P, Van Eijk R, Oosting J, Verweij J, Terrier P, Schneider U, Sciot R, Blay J, Hogendoorn P, on behalf of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Cell cycle/apoptosis molecule expression correlates with imatinib response in patients with advanced gastrointestinal stromal tumors. Clinical Cancer Research 2009; 15(12): 4191-4198. 10. Le Cesne A, Van Glabbeke M, Verweij J, Casali PG, Findlay M, Reichardt P, Issels R, Judson I, Schoffski P, Leyvraz S, Bui B, Hogendoorn PC, Sciot R, Blay JY. Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the Intergroup EORTC-ISG-AGITG phase III trial. Journal of Clinical Oncology 2009;27(24): 3969–3974. Published online 20 Jul 2009. 12. MetaGIST: Gastrointestinal Stromal Tumor Meta-Analysis Group, Verweij J, Blay J, Debiec-Rychter M, Demetri G, Heinrich M, Borden E, Blanke C, Crowley J, Rankin C, Casali P, Von Mehren M, Fletcher C, Fletcher J, Owzar K, Zalcberg J, Simes J, Bramwell V. Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1640 patients. Journal of Clinical Oncology 2010; 28(7): 1247–1253 13. Hohenberger P, Bonvalot S, Litiere S, Rutkowski P, van Coevorden F, Meeus P, Marréaud S, Raventos VA, Kotasek D, Padbury R, Van der Graaf W, Gronchi A. Surgical resection of metastatic GIST on imatinib delays recurrence and death: results of a cross-match comparison in the EORTC intergroup study 62005, aimed at assessing the clinical activity of imatinib at two dose levels in patients with unresectable or metastatic GIST Connective Tissue Oncology Society; 15–18 Oct 2014; Berlin. 14. Lee CK, Goldstein D, Gibbs E, Joensuu H, Zalcberg J, Verweij J, Casali PG, Maki RG, Cioffi A, McArthur G, Lord SJ, Yip D, Kanjanapan Y, Rutkowski P. Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib. European Journal of Cancer. Published online 25 Mar 2015 15. Current JCO Casali PG, Zalcberg J, Le Cesne A, Reichardt P, Blay J-Y, Lindner L, Judson I, Schöffski P, Bauer J, Italiano A, Grünwald V, Lopez Pousa A, Kotasek D, Sleijfer S, Kerst JM, Rutkowski P, Fumagalli E, Hogendoorn PCW, Litière S, Marreaud S, Van der Graaf W, Gronchi A, Verweij, on behalf of EORTC STBSG, ISG, AGITG. Ten-year progression-free and overall survival in patients with unresectable or metastatic gastrointestinal stromal tumours (GIST). Long-term analysis of the EORTC, ISG, AGITG intergroup Phase III randomized trial on imatinib at two dose levels. Accepted JCO October 2016
Query!
Public notes
Query!
Contacts
Principal investigator
Name
35434
0
Prof John Zalcberg
Query!
Address
35434
0
Department of Epidemiology and Preventative Medicine
School of Public Health
Monash University
The Alfred Centre
6/99 Commercial Rd
Melbourne VIC 3004
Query!
Country
35434
0
Australia
Query!
Phone
35434
0
+61 3 9903 0388
Query!
Fax
35434
0
Query!
Email
35434
0
[email protected]
Query!
Contact person for public queries
Name
9327
0
Advanced GIST trial coordinator
Query!
Address
9327
0
NHMRC Clinical Trials Centre
Locked Bag 77
Camperdown NSW 1450
Query!
Country
9327
0
Australia
Query!
Phone
9327
0
+61 2 9562 5000
Query!
Fax
9327
0
+61 2 95625094
Query!
Email
9327
0
[email protected]
Query!
Contact person for scientific queries
Name
255
0
Professor John Zalcberg
Query!
Address
255
0
School of Public Health
Monash University
The Alfred Centre
6/99 Commercial Rd
Melbourne VIC 3004
Query!
Country
255
0
Australia
Query!
Phone
255
0
+61 3 9903 0388
Query!
Fax
255
0
+61 3 9903 0556
Query!
Email
255
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF